Logo image of KNW

KNOW LABS INC (KNW) Stock Fundamental Analysis

NYSEARCA:KNW - NYSE Arca - US4992382022 - Common Stock - Currency: USD

3.02  -0.02 (-0.66%)

After market: 2.92 -0.1 (-3.31%)

Fundamental Rating

0

Taking everything into account, KNW scores 0 out of 10 in our fundamental rating. KNW was compared to 188 industry peers in the Health Care Equipment & Supplies industry. KNW has a bad profitability rating. Also its financial health evaluation is rather negative. KNW is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

KNW had negative earnings in the past year.
KNW had a negative operating cash flow in the past year.
In the past 5 years KNW always reported negative net income.
KNW had a negative operating cash flow in each of the past 5 years.
KNW Yearly Net Income VS EBIT VS OCF VS FCFKNW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

KNW has a Return On Assets of -1751.72%. This is amonst the worse of the industry: KNW underperforms 99.47% of its industry peers.
Industry RankSector Rank
ROA -1751.72%
ROE N/A
ROIC N/A
ROA(3y)-196.65%
ROA(5y)N/A
ROE(3y)-930.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KNW Yearly ROA, ROE, ROICKNW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KNW so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KNW Yearly Profit, Operating, Gross MarginsKNW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

0

2. Health

2.1 Basic Checks

KNW has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, KNW has a worse debt to assets ratio.
KNW Yearly Shares OutstandingKNW Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
KNW Yearly Total Debt VS Total AssetsKNW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -271.62, we must say that KNW is in the distress zone and has some risk of bankruptcy.
KNW has a Altman-Z score of -271.62. This is amonst the worse of the industry: KNW underperforms 98.40% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -271.62
ROIC/WACCN/A
WACCN/A
KNW Yearly LT Debt VS Equity VS FCFKNW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

KNW has a Current Ratio of 0.07. This is a bad value and indicates that KNW is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.07, KNW is doing worse than 97.87% of the companies in the same industry.
KNW has a Quick Ratio of 0.07. This is a bad value and indicates that KNW is not financially healthy enough and could expect problems in meeting its short term obligations.
KNW has a worse Quick ratio (0.07) than 97.87% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
KNW Yearly Current Assets VS Current LiabilitesKNW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.76% over the past year.
The Revenue for KNW has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)52.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.8%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KNW will show a small growth in Earnings Per Share. The EPS will grow by 1.18% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25%
EPS Next 2Y8.56%
EPS Next 3Y1.18%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNW Yearly Revenue VS EstimatesKNW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2026 2M 4M 6M
KNW Yearly EPS VS EstimatesKNW Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -5 -10 -15 -20

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KNW. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KNW. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KNW Price Earnings VS Forward Price EarningsKNW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNW Per share dataKNW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.56%
EPS Next 3Y1.18%

0

5. Dividend

5.1 Amount

KNW does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

KNOW LABS INC

NYSEARCA:KNW (6/10/2025, 8:04:02 PM)

After market: 2.92 -0.1 (-3.31%)

3.02

-0.02 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-12 2025-08-12
Inst Owners5.52%
Inst Owner ChangeN/A
Ins Owners18.59%
Ins Owner Change1.29%
Market Cap22.65M
Analysts80
Price Target40.8 (1250.99%)
Short Float %6.39%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3900%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3900%
EPS NY rev (1m)0%
EPS NY rev (3m)-3900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.51
EYN/A
EPS(NY)-9.29
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.2
OCFYN/A
SpS0
BVpS-0.78
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1751.72%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.65%
ROA(5y)N/A
ROE(3y)-930.37%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z -271.62
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)147.16%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.8%
EPS Next Y25%
EPS Next 2Y8.56%
EPS Next 3Y1.18%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.63%
OCF growth 3YN/A
OCF growth 5YN/A